Q3 2024 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Key Points
- Ginkgo Bioworks Holdings Inc (DNA) reported a 17% increase in active programs year over year, indicating growth in their cell engineering platform.
- The company successfully reduced R&D and G&A expenses significantly due to restructuring efforts, reflecting effective cost management.
- Ginkgo Bioworks Holdings Inc (DNA) achieved a significant improvement in adjusted EBITDA, which was negative $20 million, down from negative $84 million in Q3 2023.
- The company has made progress in its site consolidation efforts, moving faster than planned, which is expected to further reduce costs.
- Ginkgo Bioworks Holdings Inc (DNA) has launched new tools offerings, such as data points, which are gaining traction and have already signed deals with major pharma companies.
- The biosecurity business experienced a decline in revenue and gross margins quarter over quarter, indicating volatility in this segment.
- Despite cost reductions, the cash burn in Q3 was high due to nonrecurring items like litigation settlements and employee severance.
- The company's net loss includes several non-cash items, complicating the assessment of its financial health.
- Ginkgo Bioworks Holdings Inc (DNA) is facing challenges in the solutions business due to the long timeframes for milestones and royalties to materialize.
- The company is undergoing significant restructuring, which includes a 35% reduction in workforce, potentially impacting operations and morale.
Portions of this transcript marked (audio in progress) indicate audio problems. The missing text will be supplied if a replay becomes available.
(audio in progress) Shift from small early-stage customers tumors, along with the change made as part of the restructuring, we supported a total of 136 active programs across 81 customers on the cell engineering platform. This represents a 17% increase in active programs each year over year.
As we discussed at our Q1 and Q2 earnings calls, the nature of programs that we take some of ours has evolved following our recent adjustments to commercial terms and the launch of our debt offering while still very early days.
This slide gives you some detail on how the nature of programs is changing. We added a total of 25 new bids and contracts in Q3 2024, of which 11 were generally comparable in size and scope just historically reported new programs and were included in the current active program count on the prior slide.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
